Possible Diagnostic Test for Crohn's Disease by Use of Buccal Mucosa

Walker, J.E.G.

doi:10.1016/s0140-6736(78)92648-x

Cited by 14 publications

(5 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[51][52][53][54][55][56][57] Some authors are referring to them as 'CD of the mouth'. 58 The typical linear fissures and ulcerations have the same histopathological features of intestinal CD 59 (Figure 3). Orofacial CD is a specific manifestation of CD (5-15% of patients) and is regarded as an acute oral form of the disease with ulcer formation.…”

Section: Spectrum Of Oral Manifestations In Ibdmentioning

confidence: 84%

“…The phenomenon of oral ulcers and cobblestoning appearance in the mouth of patients with CD has been nicely illustrated in a significant number of cases . Some authors are referring to them as ‘CD of the mouth’ . The typical linear fissures and ulcerations have the same histopathological features of intestinal CD (Figure ).…”

Section: Spectrum Of Oral Manifestations In Ibdmentioning

confidence: 97%

See 1 more Smart Citation

Review article: non‐malignant oral manifestations in inflammatory bowel diseases

Κατσάνος

Torres

Roda

et al. 2015

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Summary Background Patients with inflammatory bowel diseases (IBD) may present with lesions in their oral cavity. Lesions may be associated with the disease itself representing an extraintestinal manifestation, with nutritional deficiencies or with complications from therapy. Aim To review and describe the spectrum of oral nonmalignant manifestations in patients with inflammatory bowel diseases [ulcerative colitis (UC), Crohn's disease (CD)] and to critically review all relevant data. Methods A literature search using the terms and variants of all nonmalignant oral manifestations of inflammatory bowel diseases (UC, CD) was performed in November 2014 within Pubmed, Embase and Scopus and restricted to human studies. Results Oral lesions in IBD can be divided into three categories: (i) lesions highly specific for IBD, (ii) lesions highly suspicious of IBD and (iii) nonspecific lesions. Oral lesions are more common in CD compared to UC, and more prevalent in children. In adult CD patients, the prevalence rate of oral lesions is higher in CD patients with proximal gastrointestinal tract and/or perianal involvement, and estimated to range between 20% and 50%. Oral lesions can also occur in UC, with aphthous ulcers being the most frequent type. Oral manifestations in paediatric UC may be present in up to one‐third of patients and are usually nonspecific. Conclusions Oral manifestations in IBD can be a diagnostic challenge. Treatment generally involves managing the underlying intestinal disease. In cases presenting with local disabling symptoms and impaired quality of life, local and systemic medical therapy must be considered and/or oral surgery may be required.

show abstract

Section: Spectrum Of Oral Manifestations In Ibdmentioning

confidence: 84%

Section: Spectrum Of Oral Manifestations In Ibdmentioning

confidence: 97%

Review article: non‐malignant oral manifestations in inflammatory bowel diseases

Κατσάνος

Torres

Roda

et al. 2015

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…In CD, the first report on humoral autoimmunity referred to the occurrence of autoAbs against buccal mucosa cells [38] and, later on, to exocrine pancreas (PAb) ascertained by IFA [39,40]. Whereas autoimmunity in UC could be linked to the site of colonic inflammation, the occurrence of PAb in CD remained an unsolved enigma until recently.…”

Section: Humoral Autoimmune Responses In Pscmentioning

confidence: 99%

The search for the Holy Grail: autoantigenic targets in primary sclerosing cholangitis associated with disease phenotype and neoplasia

Lopens

Krawczyk

Papp

et al. 2020

Autoimmun Highlights

View full text Add to dashboard Cite

Unlike in other autoimmune liver diseases such as autoimmune hepatitis and primary biliary cholangitis, the role and nature of autoantigenic targets in primary sclerosing cholangitis (PSC), a progressive, chronic, immune-mediated, life threatening, genetically predisposed, cholestatic liver illness, is poorly elucidated. Although anti-neutrophil cytoplasmic antibodies (ANCA) have been associated with the occurrence of PSC, their corresponding targets have not yet been identified entirely. Genome-wide association studies revealed a significant number of immune-related and even disease-modifying susceptibility loci for PSC. However, these loci did not allow discerning a clear autoimmune pattern nor do the therapy options and the male gender preponderance in PSC support a pathogenic role of autoimmune responses. Nevertheless, PSC is characterized by the co-occurrence of inflammatory bowel diseases (IBD) demonstrating autoimmune responses. The identification of novel autoantigenic targets in IBD such as the major zymogen granule membrane glycoprotein 2 (GP2) or the appearance of proteinase 3 (PR3) autoantibodies (autoAbs) have refocused the interest on a putative association of loss of tolerance with the IBD phenotype and consequently with the PSC phenotype. Not surprisingly, the report of an association between GP2 IgA autoAbs and disease severity in patients with PSC gave a new impetus to autoAb research for autoimmune liver diseases. It might usher in a new era of serological research in this field. The mucosal loss of tolerance against the microbiota-sensing GP2 modulating innate and adaptive intestinal immunity and its putative role in the pathogenesis of PSC will be elaborated in this review. Furthermore, other potential PSC-related autoantigenic targets such as the neutrophil PR3 will be discussed. GP2 IgA may represent a group of new pathogenic antibodies, which share characteristics of both type 2 and 3 of antibody-mediated hypersensitive reactions according to Coombs and Gell.

show abstract

“…First reports on humoral autoimmunity in CrD can be traced back to the late 1970s. Walker described a possible diagnostic test for CrD by the use of buccal mucosa as a substrate in indirect immunofluorescence (IIF) for the detection of respective autoantibodies [13]. Loss of immunological tolerance observed in CrD and UC has been reported mainly for exocrine pancreatic, neutrophilic, and intestinal goblet cellular antigens [14][15][16].…”

Section: Autoimmunity In Crohn's Diseasementioning

confidence: 99%

Crohn’s disease specific pancreatic antibodies: clinical and pathophysiological challenges

Roggenbuck¹,

Reinhold

Schierack

et al. 2014

Clinical Chemistry and Laboratory Medicine

View full text Add to dashboard Cite

Crohn's disease (CrD) and ulcerative colitis (UC) are the main inflammatory bowel diseases (IBD). IBDspecific humoral markers of autoimmunity in the form of autoantibodies have been reported first in the late 1950s by demonstrating the occurrence of autoimmunity in UC, while humoral autoimmunity in CrD can be traced back to the 1970s. Ever since, the pathophysiological role of autoimmune responses in IBDs has remained poorly understood. Notwithstanding, autoreactive responses play a major role in inflammation leading to overt IBD. In CrD, approximately 40% of patients and < 20% of patients with UC demonstrate loss of tolerance to antigens of the exocrine pancreas. Glycoprotein 2 (GP2) has been identified as a major autoantigenic target of the so-called pancreatic antibodies. The previously unsolved contradiction of pancreatic autoreactivity and intestinal inflammation in IBD was elucidated by demonstrating the expression of GP2 at the site thereof. Intriguingly, GP2 has been reported to be a receptor on microfold cells of intestinal Peyer's patches, which are believed to represent the origin of CrD inflammation. The development of immunoassays for the detection of antibodies to GP2 has paved the way to investigate the association of such antibodies with the clinical phenotype in CrD. Given the recently discovered immunomodulating role of GP2 in innate and adaptive intestinal immunity, this association can shed further light on the pathophysiology of IBD. In this context, the association of anti-GP2 autoantibodies as novel CrD-specific markers with the clinical phenotype in CrD will be discussed in this review.

show abstract

Possible Diagnostic Test for Crohn's Disease by Use of Buccal Mucosa

Cited by 14 publications

References 1 publication

Review article: non‐malignant oral manifestations in inflammatory bowel diseases

Review article: non‐malignant oral manifestations in inflammatory bowel diseases

The search for the Holy Grail: autoantigenic targets in primary sclerosing cholangitis associated with disease phenotype and neoplasia

Crohn’s disease specific pancreatic antibodies: clinical and pathophysiological challenges

Contact Info

Product

Resources

About